Cortical myoclonus

Active Ingredient: Piracetam

Indication for Piracetam

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Treatment of cortical myoclonus, should be used in combination with other anti-myoclonic therapies.

For this indication, competent medicine agencies globally authorize below treatments:

7.2-20 g daily in two or three sub-doses


Dosage regimens

Regimen A: Oral, between 7.2 grams piracetam and 20 grams piracetam, divided daily, 2 to 4 doses in total.

Regimen B: Intravenous, in total between 7.2 grams piracetam and 24 grams piracetam, daily.

Regimen C: Parenteral, in total between 7.2 grams piracetam and 24 grams piracetam, daily.

Detailed description

The daily dosage should begin at 7.2 g, increasing by 4.8 g every three or four days up to a maximum of 20 g/day, in two or three sub-doses.

Treatment with other anti-myoclonic medicinal products should be maintained at the same dosage. Depending on the clinical benefit obtained, the dosage of other such medicinal products should be reduced, if possible.

Once started, treatment with piracetam should be continued for as long as the original cerebral disease persists. In patients with an acute episode, spontaneous evolution may occur over time and an attempt should be made every 6 months to decrease or discontinue the medicinal treatment. This should be done by reducing the dose of piracetam by 1.2g every two days (every three or four days in the case of a Lance and Adams syndrome, in order to prevent the possibility of sudden relapse or withdrawal seizures).

When parenteral administration is needed (e.g. swallowing difficulties, unconsciousness) piracetam can be administered intravenously at the same recommended daily dose.

  • The solution for injection will be administered intravenously over several minutes.
  • The solution for infusion will be administered continuously at the recommended daily dose over a 24-hour period.


Adjustment of the dose is recommended in elderly patients with compromised renal function. For long term treatment in the elderly, regular evaluation of the creatinine clearance is required to allow dosage adaptation if needed.

Dosage considerations

Piracetam administered orally may be taken with or without food.

Active ingredient


Piracetam’s mode of action in cortical myoclonus is as yet unknown. Piracetam exerts its haemorrheological effects on the platelets, red blood cells, and vessel walls by increasing erythrocyte deformability and by decreasing platelet aggregation, erythrocyte adhesion to vessel walls and capillary vasospasm.

Read more about Piracetam

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.